These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 10917205)

  • 1. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P; Zheng C; Moyana T; Xiang J
    Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
    Hiroishi K; Tüting T; Tahara H; Lotze MT
    Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J; Qi Y; Chen Y
    Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule.
    Lu Y; Yamauchi N; Koshita Y; Fujiwara H; Sato Y; Fujii S; Takahashi M; Sato T; Kato J; Yamagishi H; Niitsu Y
    Gene Ther; 2001 Apr; 8(7):499-507. PubMed ID: 11319616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha gene-modified dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity in mice.
    Zhang W; Yang H; Wang Z; Jim X
    Chin Med J (Engl); 2002 Dec; 115(12):1767-71. PubMed ID: 12622920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
    Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined CD4+ Th1 effect and lymphotactin transgene expression enhance CD8+ Tc1 tumor localization and therapy.
    Huang H; Bi XG; Yuan JY; Xu SL; Guo XL; Xiang J
    Gene Ther; 2005 Jun; 12(12):999-1010. PubMed ID: 15789061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.